Wegman David H, Major Elaine
School of Health and Environment, University of Massachusetts Lowell, Lowell, Massachusetts, USA.
Am J Ind Med. 2009 Feb;52(2):172-5. doi: 10.1002/ajim.20652.
Editorial policy for biomedical journals increasingly calls on authors to affirm that approval was received from an Institutional Review Board (IRB) (or equivalent) prior to initiating any human subjects research presented in a manuscript submitted for publication. For most investigations and investigators this does not present any problem. However, when research is carried out in a setting where there is no IRB, should editors consider a report of such a study based on the merits alone? There is no simple answer to this question. This commentary explores aspects of the question and presents issues to be considered in developing an answer. Am. J. Ind. Med. 52:172-175, 2009. (c) 2008 Wiley-Liss, Inc.
生物医学期刊的编辑政策越来越多地要求作者确认，在启动提交发表的稿件中所呈现的任何人体研究之前，已获得机构审查委员会（IRB）（或同等机构）的批准。对于大多数研究和研究者来说，这没有任何问题。然而，当研究是在没有IRB的环境中进行时，编辑是否应该仅基于研究本身的价值来考虑发表这样一项研究的报告呢？这个问题没有简单的答案。本评论探讨了该问题的各个方面，并提出了在得出答案时需要考虑的问题。《美国工业医学杂志》52:172 - 175，2009年。（c）2008威利 - 利斯公司。
